Neptune Reports Fiscal 2012 Results
2012年5月25日 - 9:00PM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX:NTB) reports today its
consolidated financial results for the fiscal year ended February
29, 2012, announces corporate reorganization and the holding of an
earning call.
Fiscal year ended February 29, 2012 Financial
Results
Nutraceutical Business Results
- Nutraceutical revenues increased by 15% to a record
$19,113,000, for the fiscal year ended February 29, 2012, up from
$16,583,000 achieved during the corresponding period ended February
28, 2011.
- Net income from nutraceutical business improved by 136% and
reached a net income of $2,384,000 for the fiscal year ended
February 29, 2012, compared to a net income of $1,010,000 for the
corresponding period ended February 28, 2011.
- EBITDA from nutraceutical business for the fiscal year ended
February 29, 2012 reached $2,690,000, compared to$2,818,000
obtained during the corresponding period ended February 28,
2011.
Consolidated Results
- Revenues increased by 15% to $19,124,000 for the fiscal year
ended February 29, 2012, up from $16,583,000 achieved during the
corresponding period ended February 28, 2011.
- Earnings for the year ended February 29, 2012 resulted into a
net loss of ($4,593,000) compared to a net loss of ($1,693,000),
for the corresponding period ended February 28, 2011.
- Consolidated EBITDA for the fiscal year ended February 29, 2012
was ($2,593,000), compared to $258,000 obtained during the
corresponding period ended February 28, 2011.
Three-Month Period ended February 29, 2012 Financial
Results
Nutraceutical Business Results
- Nutraceutical revenues for the three-month period ended
February 29, 2012 increased by 31% to a record $5,357,000, compared
to $4,078,000 for the three-month period ended February 28,
2011.
- Earnings from nutraceutical business for the three-month period
ended February 29, 2012 resulted into a net profit of $1,379,000
compared to a net loss of ($985,000), for the three-month period
ended February 28, 2011.
- EBITDA from nutraceutical business for the three-month period
ended February 29, 2012 reached $185,000, compared to a negative
($188,000) achieved during the three-month period ended February
28, 2011.
Consolidated Results
- Revenues for the three-month period ended February 29, 2012
totalled $5,368,000 compared to $4,078,000 for the three-month
period ended February 28, 2011.
- Earnings for the three-month period ended February 29, 2012
resulted into a net loss of ($134,000) or ($0.01) per share,
compared to a net loss of ($2,212,000) or ($0.04) per share, for
the three-month period ended February 28, 2011.
- EBITDA for the three-month period ended February 29, 2012
reached ($775,000), compared to ($1,304,000) achieved during the
three-month period ended February 28, 2011.
"Revenues reached a record level of $19.1M directly attributable
to Neptune's operational, nutraceutical business segment and
complementary marketing strategies. Reaching record revenues year
in and year out strongly reflects the kind of company Neptune is
along with effective marketing efforts and creativity" stated
Frédéric Harland, Director of Finance.
"We are extremely pleased with Neptune's latest fiscal year
outstanding results and profitability, and building on this
momentum for fiscal year 2013 where revenues growth will be
Neptune's primary focus" stated André Godin, Chief Financial
Officer.
Corporate Reorganization
Neptune also announces a series of management changes and
restructuring initiatives designed to strengthen the Corporation
and position it for long-term success.
''The actions we are announcing today will provide the
organizational structure and leadership needed to execute our
strategic plan and fulfill the enormous promise of this company,"
said Henri Harland, President and Chief Executive Officer.
Key components of the management changes and restructuring
initiatives include:
- Harland Waksal's nomination on the Board of Directors,
- Dr. Tina Sampalis' nomination as Chief Global Strategic Officer
(CGSO) of Neptune, Acasti and NeuroBiopharm,
- Wael Massrieh's promotion to Vice President Scientific Affairs;
he will oversee Neptune's R&D program,
- Eric Simard's promotion to Vice President Science &
Development; he will oversee all innovation of manufacturing
process as well as clinical research.
- Michel Timperio's promoted to Vice President Global Sales; he
will oversee sales & business development.
''These changes to date bring together an outstanding group of
seasoned leaders, with a broad range of talents and abilities and a
proven history of delivering results and achieving objectives,"
said Henri Harland. "The Corporation and all its stakeholders
stand to benefit considerably from their collective knowledge,
experience and expertise. These changes were, in part,
designed to put greater emphasis on stimulating sales growth,
assessing our business portfolio opportunities and expanding
operating profit margins" he added.
Management Earning Call
Neptune will be holding a conference call and webcast on
Thursday, May 31th, 2012 at 4:30 pm ET.
The main topics to be discussed on the call include:
- Year End financial results,
- Commercial progress,
- Plant expansion,
- Intellectual property,
- NeuroBioPharm,
- Acasti Pharma Update.
The conference call hosts are:
- Henri Harland, President & Chief Executive Officer;
and
- André Godin, Chief Financial Officer.
The details relating to the conference call will be announced on
the week of May 28th 2012.
Management will accept questions by telephone during the Q&A
period at the end of the presentation. Questions can also be
forwarded in advance or during the presentation to the following
email address: f.harland@neptunebiotech.com.
An archived recording of the webcast will be available on
Neptune's website (www.neptunebiotech.com) two hours after the
webcast.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024